Metabolomics in the Diagnosis and Pharmacotherapy of Lung Diseases

Author(s): Philippe Devillier, Helene Salvator, Emmanuel Naline, Louis-Jean Couderc, Stanislas Grassin-Delyle*

Journal Name: Current Pharmaceutical Design

Volume 23 , Issue 14 , 2017

Become EABM
Become Reviewer
Call for Editor


Metabolomics is of the increasing interests in medical research and the study of respiratory diseases. This novel type of small molecule analysis can be performed not only on conventional biological samples such as plasma or urine but also on sputum, bronchoalveolar fluid, exhaled breath condensate or exhaled breath itself (which is particularly relevant for research on respiratory diseases). On one hand, powerful analytical methodologies (including mass spectrometry and nuclear magnetic resonance spectroscopy) are labour-intensive but enable the exhaustive identification of metabolites. On the other hand, electronic noses can be used for exhaled breath analysis. Although the latter devices do not contain metabolite-specific sensors, they produce a condition- or treatment-specific “breathprint” based on pattern recognition. Breath analysis with electronic noses is noninvasive, and can be performed at the bedside in real time. Here, we review the literature on metabolomics studies in respiratory medicine, with a focus on the evaluation of responses to pharmacotherapy.

Keywords: Metabolomics, volatolomics, lung disease, electronic nose.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2017
Page: [2050 - 2059]
Pages: 10
DOI: 10.2174/1381612823666170130155627
Price: $65

Article Metrics

PDF: 43